The BioMed X Institute
19.12.2023 10:03:15 CET | ACCESS Newswire | Press release
German research institute BioMed X and Ono Pharmaceutical, a Japanese pharmaceutical company, started a new joint research project on cancer immunotherapies.
HEIDELBERG, GERMANY / ACCESSWIRE / December 19, 2023 / BioMed X announced today a new joint research project with Ono Pharmaceutical Co., Ltd, marking the start of the collaboration between the German biomedical research institute and one of the largest pharmaceutical companies in Japan. The project entitled "New Strategies to Engage Neutrophils in Solid Tumors" will be hosted by the BioMed X Institute in Heidelberg, Germany. The goal of this research project is to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils.
Developing immunotherapies that target T cells has proved highly effective, and it is still a rapidly evolving research area. However, many patients remain resistant to these therapies, necessitating the development of novel immunological strategies. The presence of neutrophils in solid tumors has been well-documented, albeit their role in the tumor microenvironment seems to be paradoxical according to the data accumulated thus far. By uncovering novel neutrophil biology, this project aims to leverage their functions to design novel immunotherapies.
The new research team will join nine other research groups at the BioMed X Institute in Heidelberg, Germany. Researchers who are interested in becoming part of this new research group are invited to respond to this international call for application by submitting a project proposal via the BioMed X Career Space at https://career.bio.mx/call/2023-BMX-C03 before February 18, 2024.
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "Oncology and immunology, including tumor immunology, are key areas of expertise at BioMed X. We are proud and honored that Ono has chosen our institute to develop new strategies for engaging neutrophils in cancer therapy".
Toichi Takino, Senior Executive Officer/Executive Director, Discovery & Research at Ono Pharmaceutical: "We are very pleased to form a partnership with BioMed X in our mission dedicated to overcoming cancer. This innovative research collaboration will engage us with highly talented scientists around the world who possess unique ideas for immunotherapy utilizing neutrophils. We believe that the research team established through this collaboration will lead to the discovery of the next generation of immunotherapy with us".
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
About Ono
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company's website at https://www.ono-pharma.com/en.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
View the original press release on newswire.com.
SOURCE: BioMed X Institute
To view this piece of content from stats.newswire.com, please give your consent at the top of this page. To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Inc. (NASDAQ: DVLT) and WiSA Technologies Announce the Goho LS7 2.0 and 5.1 Home Theater Systems with WiSA E Wireless Connectivity23.6.2026 16:10:00 CEST | Press release
WiSA Technologies, a Datavault AI Company, powers wireless connectivity for two new home theater and karaoke systems from Goho, a brand of Goldhorn WISA E solves critical cross-brand interoperability problems, providing ubiquity on an enterprise scale for another of the world's premium acoustic brands. PHILADELPHIA, PA / ACCESS Newswire / June 23, 2026 / Datavault AI Inc. (NASDAQ:DVLT), through its Acoustic Sciences division's WiSA Technologies, today announced integration of the WiSA E Enterprise module in the new LS7 2.0 and 5.1 wireless home audio and karaoke systems from Goho, a brand of Goldhorn. These two stunning new systems are designed to bring high-definition two-channel and immersive 5.1 channel surround sound into the home entertainment environment with the simplicity and reliability of WiSA wireless audio transmission. "Goldhorn has built a strong reputation for delivering premium audio components to the mobile audio market, and we are very excited to enter the home audio
FINOS Launches AI Fund to Amplify the Collective Voice of the Financial Services Industry and Accelerate Responsible Agentic AI Adoption23.6.2026 10:00:00 CEST | Press release
Founding premier members DTCC, Morgan Stanley, RBC and NatWest join forces to collectively invest in open source AI, to advance common governance, controls, specifications, reference implementations, and intra and inter-firm agentic workflows for financial services, helping the industry shape safer AI adoption, reduce fragmentation, and accelerate real-world implementation. LONDON, UK / ACCESS Newswire / June 23, 2026 / The Fintech Open Source Foundation (FINOS) today announced the establishment of the FINOS AI Fund and the formation of its dedicated Governing Board. Anchored by Founding Premier Members The Depository Trust & Clearing Corporation (DTCC), Morgan Stanley, Royal Bank of Canada (RBC), and NatWest, the Fund is designed to help the industry collectively shape the governance, standards, and implementation foundations needed for responsible agentic AI adoption in regulated financial services. The Case for an Industry-Led AI Approach in Financial Services General AI technology
CTO Confidence in Scaling AI Falls for Third Straight Year, Akkodis Report Finds23.6.2026 06:45:00 CEST | Press release
"What CTOs Think 2026: Scaling the agentic enterprise with confidence" reveals for the first time, innovation, not efficiency, as the primary driver of digital investment, signaling a move from cost-focused optimization toward growth. ZURICH, SWITZERLAND / ACCESS Newswire / June 23, 2026 / New research released today by Akkodis, a global leader in digital engineering consulting and part of the Adecco Group, shows that CTO confidence in scaling AI is declining, falling to 48% in 2026 from 82% in 2024 - even as AI adoption accelerates and enterprises face growing pressure to turn ambition into execution at scale. Image: What CTOs Think 2026: Scaling the agentic enterprise with confidence. Source: Akkodis The third edition of Akkodis' What CTOs Think report, What CTOs Think 2026: Scaling the agentic enterprise with confidence, features insights from 500 Chief Technology Officers (CTOs) as part of the Adecco Group's Business Leaders 2026 research of 2,000 C-suite executives, The human prem
LiberNovo Prime Sale Fully Launches June 23: Full Chair Lineup and Accessories, Up to 49% Off23.6.2026 04:00:00 CEST | Press release
The limited Omni Premium Bundle headlines a flash sale across the EU and UK, stacked with tiered gifts, a prize wheel, and triple loyalty points, from June 23 through July 11. HONG KONG, HK / ACCESS Newswire / June 22, 2026 / LiberNovo today opened one of its biggest sales of the year. From June 23 through July 11, the entire collection goes on sale across the EU and UK with savings of up to 49% off, and the headline deal is the Omni Premium Bundle: a limited flash-sale price on the original Omni, starting from €939 ( £869) up to 49% off, the chair that started it all, available only while clearance stock lasts. Accessories and the rest of the range join at Prime Sale pricing too, making it the best time of the year to build your complete setup. Every LiberNovo chair is built on the world's first dynamic ergonomic design. A flexible backrest bends and moves with you as you shift, lean, and change position, so your support follows your body instead of holding you in one pose. A powered
Leggett Dynamics Launches Mid-Class Massage System & Makes Luxury Comfort Accessible on High-Volume Programs22.6.2026 13:00:00 CEST | Press release
DETROIT, MI / ACCESS Newswire / June 22, 2026 / Leggett Dynamics today launched its Mid-Class Massage System (MCM), a breakthrough non-electronic innovation that makes premium massage more accessible beyond the luxury vehicle segment. Now in production with a global OEM, MCM was also shortlisted for the 2026 Auto Tech Partnership Award for industry-leading innovation and collaboration. Breakthrough by Design MCM creates a distinctive massage experience with a compact 30 x 35 mm module that uses the Coandă effect, an air jet's natural tendency to follow a curved surface. With no electronics or moving parts, it reduces complexity and cost, making a premium experience accessible to more vehicle segments and consumers. Balancing Innovation, Speed and Cost "Automakers must balance innovation, speed and cost while consumers expect more personalized, affordable, premium experiences," said Julien Rea, VP of Global Innovation & Engineering at Leggett Dynamics. "Leggett Dynamics' Mid-Class Massa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom